ATLANTA, July 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Macrogenics, Inc. (“MGNX” or the “Company”) (NASDAQ: MGNX). The lawsuit alleges that Defendants provided investors with material information concerning MGNX’s early interim safety data from MGNX’s ongoing TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) in patients with metastatic astration – resistant prostate cancer (mCRPC) that materially mislead and/or failed to disclose information pertinent to investors.
If you bought shares of MGNX between March 7, 2024 and May 9, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/macrogenics/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is September 24, 2024.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
![](https://ml.globenewswire.com/media/ODU2YmMxZjYtMDhmNi00MDg5LTllZWYtN2E3NThkYjRiOTIyLTExOTIzMzY=/tiny/Holzer-Holzer.png)